Cidara Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Cidara Therapeutics

07/05/2024 13:12

* Cidara Therapeutics Inc  CDTX.OQ   CDTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * The San Diego California-based  company is expected to
report a
75.8% decrease in revenue to $6.3 million from $25.99 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Cidara Therapeutics Inc
is for
a loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cidara
Therapeutics Inc is $40.00​, above​ its last closing price
of $13.61. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -3.19       -2.07      -0.80     Beat    61.3
 Jan. 1 2023   -3.19       -3.25      -1.80     Beat    44.6
 Jan. 1 0001   -2.04       -2.60      -2.80     Missed  -7.7​
 Mar. 31 2023  -4.24       -0.73      0.60      Beat    181.8
 ​​Jan.        -4.24       -3.35      -3.80     Missed  -13.4
 1 0001                                                 
 Sep. 30 2022  3.71        -5.60      3.40      Beat    -5.6​
 Jan. 1 0001   -5.59       -5.60      -3.80     Beat    32.1
 Mar. 31 2022  -5.54                  -5.40             8.2
 This summary was machine generated May 7 at 12:11 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)